Heparan sulphate proteoglycan in scleromyxedema promotes FGF-2 activity

Pathology Research and Practice

Volumn 198, Issue 10, 2002, Pages 701-707

  Warner, Thomas F ^a   Wrone, David A ^a   Williams, Eliot C ^a   Cripps, Derek J ^a   Mundhenke, Christoph ^a   Friedl, Andreas ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Fibroblast growth factor; Proteoglycans; Scleromyxedema

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN; CYTOKINE ANTIBODY; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; METHOXSALEN; MONOCLONAL ANTIBODY; PARAFFIN; PROTEOHEPARAN SULFATE; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; BINDING AFFINITY; CASE REPORT; CELL PROLIFERATION; COMPLEX FORMATION; FIBROBLAST; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; MALE; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN IMMOBILIZATION; PUVA; SCLERODERMA; SCLEROMYXEDEMA; SIGNAL TRANSDUCTION; SKIN NODULE; STAINING; IMMUNOHISTOCHEMISTRY; LICHENOID ERUPTION; METABOLISM; MYXEDEMA; PATHOLOGY; SKIN; SKIN DISEASE;

ADULT; FACIAL DERMATOSES; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IMMUNOHISTOCHEMISTRY; LICHENOID ERUPTIONS; MALE; MYXEDEMA; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; SKIN;

EID: 0036456970     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1078/0344-0338-00324     Document Type: Article

References (28)

1. Chang Z, Meyer K, Rapraeger AC, Friedl A (2000) Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J 14: 137-144
2. David G, Bai XM, Van der Schueren B, Cassiman JJ, Vanden Berghe H (1992) Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biology 119: 961-975
3. Dinneen AM, Dicken CH (1995) Scleromyxedema. J Amer Acad Dermatol 33: 37-43
4. Farmer ER, Hambrick GW, Shulman LE (1982) Papular mucinosis. Arch Dermatol 118: 9-13
5. Friedl A, Chang Z, Tierney A, Rapraeger AC (1997) Differential binding of FGF-2 and FGF-7 to basement membrane heparan sulfate: Comparison of normal and abnormal human tissues. Am J Pathol 150: 1443-1455
6. Friedl A, Filla M, Rapraeger AC (2001) Tissue-specific binding by FGF and FGF receptors to endogenous heparan sulfates. Methods in Molecular Biology 171: 535-546
7. Galzie Z, Kinsella AR, Smith JA (1997) Fibroblast growth factors and their receptors. Bioch & Cell Biol 75: 669-685
8. Goldfarb M (1996) Functions of fibroblast growth factors in vertebrate development. Cytokine & Growth Factor Reviews 7: 311-325
9. Gottron HA (1954) Skleromyxedem (Eine eigenartige Erscheinungsform von Myxothesaurodermie). Arch Dermatol Syph 199: 71-91
10. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC (1993) Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 268: 23906-23914
11. Harper RA, Rispler J (1978) Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 199: 545-547
12. Hill TG, Crawford JN, Rogers CC (1976) Successful management of lichen myxedematosus. Arch Dermatol 112: 67-69
13. Hisler BM, Savoy LB, Hashimoto K (1991) Improvement of scleromyxedema associated with isoretinoin therapy. J Am Acad Dermatol 24: 854-857
14. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research 59: 1935-1940
15. Johnson DE, Williams LT (1993) Structural and functional diversity in the FGF receptor multigene family. Adv in Cancer Res 60: 1-41
16. Lundin L, Larsson H, Kreuger J, Kanda S, Lindahl U, Salmivirta M, Claesson-Welsch L (2000) Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J Biol Chem 275: 24653-24660
17. MacFarlane AW, Davenport A, Verbov JL, Goldsmith HJ (1987) Scleromyxedema - successful treatment with plasma exchange and immunosuppression. Br J Dermatol 117: 653-657
18. McGee MM, Campianui G, Ramunno A, Fattorusso C, Nacci V, Lawer M, Williams DC, Zisterer DM (2001) Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptic suppressor Bcr-Abl. J Pharmacol Exp Ther 296: 31-40
19. McKee PH (1996) Degenerative and metabolic diseases. In: McKee PH (Eds) Pathology of the Skin, 1st ed., p 7. Mosby-Wolfe, NY
20. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P (1992) Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12: 240-247
21. Perry HO, Montgomery H, Stickney JM (1960) Further observations on myxedematosus. Ann Intern Med 53: 955-969
22. Pinkus H, Mehregan AH (1981) Changes of collagen and ground substance. In: Pinkus H, Mehregan AH (Eds) A Guide to Dermatohistopathology, 3rd ed., pp 292-293. Appelton-Century-Crofts, New York
23. Piper W, Hardmeier Th, Schafer E (1967) Das Skleromyxodem Arndt-Gottron: Eine paraproteinaemische Erkrankung. Schweiz Med Wochenschr 97: 829-838
24. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M (1999) Structural basis for FGF receptor dimerization and activation. Cell 98: 641-650
25. Rapraeger AC, Krufka A, Olwin BB (1991) Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252: 1705-1708
26. Rudner EJ, Mehregan A, Pinkus H (1966) Scleromyxedema. Arch Dermatol 93: 3-12
27. Yaron M, Yaron I, Yust I, Brenner S (1985) Lichen myxedematosus (sclreomyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 12: 171-175
28. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64: 841-848